Clinical Trials Logo

dcSSc clinical trials

View clinical trials related to dcSSc.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03222492 Completed - Scleroderma Clinical Trials

Brentuximab Vedotin for Systemic Sclerosis

BRAVOS
Start date: September 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activated immune cells There is evidence for CD30 involvement in SSc. This study represents the first step in determining safety and tolerability of brentuximab vedotin in SSc.